I am a board-certified hematologist and oncologist, and I am a member of a multidisciplinary team that cares for patients who are undergoing bone marrow transplantation. My particular expertise is using transplantation to treat patients with myelodysplastic syndromes and with acute myelogenous leukemia (AML) that has evolved from myelodysplastic syndromes. I am also interested in bone marrow failure syndromes including aplastic anemia and paroxysmal nocturnal hemoglobinuria. In an effort to improve the outcomes of patients undergoing transplantation, I design and monitor clinical trials of newer transplantation approaches.
Physicians in Memorial Sloan Kettering’s allogeneic transplant program use stem cells or bone marrow derived from a donor other than the patient for the transplant. We often use T cell depletion — a technique to separate out specific immune cells called T lymphocytes from the stem cell product — to reduce one of the major complications of allogeneic transplants, graft-vs-host disease (GvHD). My clinical research has proven the effectiveness of T cell depleted allogeneic transplants in treating myelodysplastic syndrome; and has established which patients derive the most leukemia-fighting benefit from allogeneic transplants. I am leading a follow-up clinical trial for this disease, using lower doses of chemotherapy before transplantation and new drugs to reduce the risk of infection afterward.
I am also interested in developing new therapies to treat patients with indolent or low-grade lymphomas. These forms of lymphoma are less sensitive than higher-grade forms of the disease to chemotherapy and/or radiation therapy, but are sensitive to the anti-lymphoma effects of an allogeneic bone marrow transplant. In collaboration with the Lymphoma Service, I am exploring potentially curative approaches for patients with low-grade lymphomas, including nonmyeloablative conditioning followed by an unmodified transplant with drug therapy to prevent GvHD.
I am Chairman of Memorial Sloan Kettering’s Bone Marrow Transplant Quality Assurance Committee, which oversees transplant services for adult and pediatric patients, and those with hematologic malignancies and germ cell tumors and ensures that these patients receive quality clinical care. I am also a member of the Center’s Institutional Review Board and Privacy Board. Membership on the IRB has provided me with a broad perspective over clinical research across the entire Center.
I am committed to teaching young physicians by example, thereby enhancing their interest and potential choice to train in this field.
I am also a reviewer for several journals including Blood, BMT, BBMT, American Journal of Hematology, Hematology, Leukemia, and JAMA.
- Clinical Expertise: Myelodysplastic Syndromes; Leukemias; Myelofibrosis; Bone Marrow Failure; Bone Marrow Transplantation; Aplastic Anemia
- Languages Spoken: English
- Education: MD, Cayetano Heredia University (Lima, Peru)
- Residencies: St. Louis Hospital (Paris)
- Fellowships: Andean Biology Institute (Lima, Peru); St. Louis Hospital (Paris)
- Board Certifications: Internal Medicine (France); Hematology/Oncology (France); Pediatric Hematology (France)
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Hugo R. Castro-Malaspina
Clinical Trials Co-Investigated by Hugo R. Castro-Malaspina
- A Phase II Study of 5'-Azacitidine to Prevent Recurrence in Patients Who Had a Donated Stem Cell Transplant for Acute Myeloid Leukemia or Myelodysplastic Syndromes
- A Phase II Study of Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post-Transplantation Donor Lymphocyte Infusions for Patients with Relapsed or High-Risk Multiple Myeloma
- A Phase II Study of T-Cell Depleted Stem Cell Boost for Adults and Children with Low Blood Counts After Allogeneic Stem Cell Transplantation
- A Reduced Intensity Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Acute Leukemia or Myelodysplasia
- Defibrotide for Patients with Hepatic Veno-Occlusive Disease
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more